Stock market analysts have maintained ‘buy’ rating on Ranbaxy Laboratories stock with an intraday target of Rs 531.

According to them, interested traders can purchase the stock above Rs 525 with a strict stop loss of Rs 521. If the stock market remains positive, the stock pricing becomes more attractive, and reach above Rs 532.
 
Shares of the company, on Monday (August 4), closed at Rs 524 on the Bombay Stock Exchange (BSE). The total volume of shares traded at the BSE was 829050. The share price has seen a 52-week high of Rs 613.70 and a low of Rs 299.90 on BSE.

Dabur India Limited, India's leading natural healthcare company, plans to invest over Rs 250 crore in the next one year to set up a greenfield facility for manufacturing a range of consumer goods and upgrade its existing facilities.

The company plans to set up a new manufacturing facility in India entailing a capital expenditure of about Rs 150 crore, which would be made in the next fiscal.

India’s leading drug maker, Aurobindo Pharma has got sanction from the US

Drug maker Strides Arcolab has informed that it has completed acquisition of 50.1% stake in Australia stock exchange listed firm Ascent Pharmahealth, formerly known as Genepharm Australasia.